This means that passive immunization with tau antibodies is usually a viable therapeutic goal and which the CSF volume of p-tau262/356 or on the microtubule binding domain (MTBD) can function a practical biomarker of tau pathology to watch tau therapeutics in scientific trials.In the same way, in co-cultures of rat Most important cells developed in